Successful treatment of delayed pressure urticaria with 300 mg of omalizumab every 14 days

Delayed pressure urticaria is a rare form of chronic inducible urticaria characterized by erythematous‐painful plaques that develop in areas of the skin exposed to prolonged pressure. Its treatment is very difficult, and its response to antihistamines is variable. Cases of delayed pressure urticaria...

Full description

Saved in:
Bibliographic Details
Published inJournal of cosmetic dermatology Vol. 20; no. 6; pp. 1897 - 1899
Main Authors Saylam Kurtipek, Gulcan, Zekey, Emre, Tuncez Akyurek, Fatma
Format Journal Article
LanguageEnglish
Published England 01.06.2021
Subjects
delayed pressure urticaria
omalizumab
omalizumab
delayed pressure urticaria
Online AccessGet full text

Cover

More Information
Summary:Delayed pressure urticaria is a rare form of chronic inducible urticaria characterized by erythematous‐painful plaques that develop in areas of the skin exposed to prolonged pressure. Its treatment is very difficult, and its response to antihistamines is variable. Cases of delayed pressure urticaria, which have been completely controlled with the use of omalizumab in recent years, have been reported.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1473-2130
1473-2165
DOI:10.1111/jocd.13764